+86 400-682-2521 | order.cn@acrobiosystems.com 注册
登录 | 注册    关注公众号 |  
微信公众号
ACRO百普赛斯_logo Recombinant Proteins iso9001 ISO13485 CNAS
热门搜索：TL1A Hot|GMP细胞因子Hot|FcRn Binding Kit (TR-FRET)New|ADC定点偶联试剂盒
ABCDEFGHIJKLMNOPQRSTUVWXYZ0-9
搜索
>产品&服务 > 抗Payload抗体——ADC PK研发核心工具

抗Payload抗体——ADC PK研发核心工具

抗Payload抗体——ADC PK研发核心工具
背景
产品优势
验证数据
验证数据
产品特征

高纯度：纯度经SDS-PAGE及SEC-MALS验证>95%；

高灵敏度：经ADC药物结合验证；

高特异性：可特异性识别小分子毒素；

方便快捷：HRP标记抗MMAE抗体可节省二抗和标记时间；

售后完善：提供完善的售后技术支持满足客户的技术指导需求。

应用场景

ADC药物临床前及临床阶段PK分析

DAR值检测

背景
表征生物药物是整个药物从开发到临床评估过程的关键步骤。抗体药物偶联物 (ADC) 结构复杂多样。其骨架是抗体，所以ADC的药代动力学与单克隆抗体有许多相似的地方。然而，偶联小分子药物导致ADC异质性增加。因此，需要对ADC进行深入的表征分析，揭示其药代动力学/药效学特征，以确保药物的安全性。
影响ADC质量的一个重要属性是DAR值和载药量分布，因此是PK方法开发的重点。常用于确认DAR值的方法包括测定总抗体(偶联和未偶联小分子毒素的抗体)、药物偶联抗体(至少偶联一个小分子毒素的抗体) 、抗体偶联药物、游离小分子毒素及其类似物。总抗体和偶联抗体通常使用酶联免疫吸附测定法 (ELISA) 测定。游离和偶联药物、分解代谢物通常用液相色谱-质谱法（LC-MS）法来分析。
为了解决ADC药物PK分析中的挑战和难点，ACROBiosystems百普赛斯发布多种高质量、高亲和力的抗Payload抗体，可用于ADC进行临床前及临床阶段的PK检测以及DAR值分析，为提高ADC药物PK分析的准确性和可靠性提供了有力的支持和保障。

ADC分析物及典型分析方法

分析物类型 分析物详情 典型的分析方法
Total Antibody Conjugated, partially unconjugated, and fully unconjugated (DAR > 0) Ligand Binding Assay
Conjugated Antibody Antibody with minimum DAR > 1 Ligand Binding Assay
Antibody-conjugated Drug Total small-molecule drug conjugated to Antibody Affinity LC-MS / Ligand Binding Assay
Unconjugated Drug Small molecule drug not conjugated to antibody LC-MS
Total Drug Total unconjugated and conjugated Drug LC-MS

血清中ADC的不同LBA分析形式

血清中ADC的不同LBA分析形式

血清中ADC的不同LBA分析形式1

产品列表
分子 货号 产品描述 订购/预购
DM-1 DM1-BLY73 Biotinylated Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified)

订购

DM-1 DM1-PLY73 HRP conjugated Monoclonal Anti-DM-1&DM-4 Antibody,Mouse IgG1

订购

DM-1 DM1-Y73 Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified)

订购

DXD DXD-BVM807 Biotinylated Anti-DXD Antibody, Mouse IgG1, Avitag™ (MALS verified)

订购

DXD DXD-M684 Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 (MALS verified)

订购

DXD DXD-PLM684 HRP conjugated Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1

订购

Eribulin ERN-BMY12b Biotinylated Rabbit Anti-Eribulin Antibody, Rabbit IgG (1M1G11)

订购

Eribulin ERN-MY2012b Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M1G11)

订购

Eribulin ERN-MY2063b Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M2B11)

订购

Eribulin ERN-PLM12b HRP conjugated Monoclonal Anti-Eribulin Antibody, Rabbit IgG (1M1G11)

订购

MMAE MME-BLS104 Biotinylated Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (MALS verified)

订购

MMAE MME-M5252 Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 (MALS verified)

订购

MMAE MME-PLS104 HRP conjugated Monoclonal Anti-MMAE&MMAF Antibody,Mouse IgG1

订购

PTX PTX-S343 Monoclonal Anti-PTX Antibody, Mouse IgG2a (MALS verified)

订购

SN38 SN8-BVM808 Biotinylated Anti-SN38 Antibody, Mouse IgG1, Avitag™ (MALS verified)

订购

SN38 SN8-M685 Monoclonal Anti-SN38 Antibody, Mouse IgG1 (MALS verified)

订购

SN38 SN8-PLM685 HRP conjugated Monoclonal Anti-SN38 Antibody, Mouse IgG1

订购

ACROBiosystems正在积极开发更多高质量抗Payload抗体。如果您有任何建议或定制要求，请点此联系我们。
验证数据
高纯度经SEC-MALS验证
抗MMAE抗体，高纯度经MALS验证

The purity of Mouse Anti-MMAE Antibody, Mouse IgG1 (Cat. No. MME-M5252) is more than 90% and the molecular weight of this protein is around 134-163 kDa verified by SEC-MALS.

抗MMAE抗体高灵敏度结合MMAE
抗MMAE抗体，高灵敏度经抗体结合验证

Immobilized Disitamab Vedotin (RC48) at 0.2 μg/mL (100 μL/well) can bind Mouse Anti-MMAE Antibody, Mouse IgG1 (Cat. No. MME-M5252) with a linear range of 0.1-2 ng/mL (QC tested).

Protocol

抗MMAE抗体，高灵敏度经抗体结合验证

Immobilized Disitamab Vedotin at 1 μg/mL (100 μL/well) can bind HRP conjugated Anti-MMAE Antibody, mAb (Cat. No. MME-PLS104) with a linear range of 0.5-16 ng/mL (QC tested).

Protocol

抗PTX抗高亲和力经PTX-ADC验证
抗PTX抗高亲和力经PTX-ADC验证

Immobilized ADC-PTX at 1 μg/mL (100 μL/well) can bind Mouse Anti-PTX Antibody, Mouse IgG2a (MALS verified) (Cat. No. PTX-S343) with a linear range of 0.106-6.767 ng/mL (QC tested).

Protocol

相关产品
ADC免疫原性评价关键——抗独特型抗体
分子 货号 产品描述 中和活性 应用
Adalimu*ab ADB-Y19 Anti-Adalimu*ab Antibodies (AY19) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Adalimu*ab ADB-Y23b Anti-Adalimu*ab Antibodies (AY23b) (recommended for PK/PD) Non-Neutralizing Antibody PK bridging ELISA; Indirect ELISA
Bevacizu*ab BEB-Y10 Anti-Bevacizu*ab Antibodies (AY10) (MALS verified, recommended for PK/PD) Neutralizing Antibody PK bridging ELISA; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-Y12 Anti-Bevacizu*ab Antibodies (AY12) (recommended for neutralizing assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-Y9 Anti-Bevacizu*ab Antibodies (AY9) (recommended for ADA assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Bevacizu*ab BEB-BY13 Biotinylated Anti-Bevacizu*ab Antibodies (AY13) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA;Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-Y27 Anti-Cetuxi*ab Antibodies (AY27) (recommended for ADA assay) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-Y31 Anti-Cetuxi*ab Antibodies (AY31) (Non-Neutralizing) Non-Neutralizing Antibody ADA assay; Indirect ELISA
Cetuxi*ab CEB-Y28 Anti-Cetuxi*ab Antibodies (AY28) Neutralizing Antibody ADA assay; Neutralizing assay; Indirect ELISA
Cetuxi*ab CEB-BY31 Biotinylated Anti-Cetuxi*ab Antibodies (AY31) (recommended for PK/PD) Non-Neutralizing Antibody PK bridging ELISA; Indirect ELISA
Rituxi*ab RIB-Y36 Anti-Rituxi*ab Antibodies (AY36) (recommended for ADA assay) Neutralizing Antibody ADA assay;Neutralizing assay; Indirect ELISA
Rituxi*ab RIB-Y37 Anti-Rituxi*ab Antibodies (AY37) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA;Neutralizing assay;Indirect ELISA
Rituxi*ab RIB-Y35c Anti-Rituxi*ab Antibodies (MALS verified) Non-Neutralizing Antibody ADA assay; Indirect ELISA
Trastuzu*ab TRB-Y5b Anti-Trastuzu*ab Antibodies (AY5b) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA
Trastuzu*ab TRB-Y1b Anti-Trastuzu*ab Antibodies (AY1b) (recommended for PK/PD) Neutralizing Antibody PK bridging ELISA; Neutralizing assay; Indirect ELISA
相关新闻

抗Payload抗体：助力ADC药物表征

DXD、SN38——ADC小分子中的“后浪”

ADC药物研发解决方案

参考文献
  • 1. Qin, Q. & Gong, L. Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices. Molecules 27, 1–17 (2022).
抗Payload抗体试用装申请
抗Payload抗体试用装申请
ACRO质量管理体系

扫一扫关注微信公众号获取ACRO最新资讯

ACROBiosystems百普赛斯生物科技股份有限公司

全国：+86 400-682-2521

北京：010-53681107

上海：021-50850665

海外：+1 800-810-0816

邮箱：（产品订购）order.cn@acrobiosystems.com

邮箱：（技术支持）tech.cn@acrobiosystems.com

邮箱：（廉洁合规）lianjie@acrobiosystems.com

地址：北京经济技术开发区宏达北路8号5号楼4层

新闻订阅

订阅

在线留言

发送
隐私政策 | 法律法规 | 网站地图 | 加入我们
©2017 ACROBiosystems中国 京公网安备 11030102010599号 京ICP备16032159号-1

消息提示

请输入您的联系方式,再点击提交！

确定